The United States government has taken a significant step in federal drug policy by signing an executive order that directs marijuana to be reclassified as a less dangerous controlled substance, potentially easing long-standing regulatory barriers. The action reflects growing political and public support for loosening strict federal controls on cannabis and expanding research into its medical applications.

Under the order, marijuana — previously categorized as a Schedule I drug, alongside substances considered to have high abuse potential and no accepted medical use — would be moved to Schedule III, a lower risk category that includes some prescription medications with moderate potential for dependence. This reclassification signals a shift in federal recognition of cannabis’s potential medical value, but it does not legalize recreational use nationwide.

The move is aimed at reducing the regulatory hurdles that have long made cannabis research difficult. Scientists and healthcare stakeholders have argued that Schedule I status severely restricted clinical studies into how cannabinoids may help treat conditions such as chronic pain and other serious health issues. By instructing the Department of Justice and the Drug Enforcement Administration to expedite the rescheduling process, the order could open the door to more robust scientific inquiry and better-informed public health guidance.

Policy advocates and some industry representatives see the change as a meaningful acknowledgment of marijuana’s legitimate medical uses, with the potential to increase access to cannabidiol (CBD) products and other derivatives for patients under physician guidance. In addition, a lower classification could reduce federal tax burdens on cannabis businesses operating legally at the state level by easing restrictions that have hindered deductions and access to banking services.

Also Read: Long term investing in Canada

However, the order stops short of full federal legalization. Cannabis possession and distribution still remain illegal under federal law, and recreational users could still face criminal penalties unless Congress passes separate legislation. The executive action also faces political pushback from some lawmakers and advocacy groups who argue that lowering the federal classification might undermine broader drug-control efforts or social priorities.

Also Read: Best long term Canadian stocks

In practical terms, the reclassification initiative is expected to influence medical research, federal enforcement priorities, and the business environment for state-legal cannabis operations. While the rescheduling process will require formal rule-making by federal agencies, the executive order marks one of the most significant shifts in U.S. cannabis policy in decades.